Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 230,287,087 papers from all fields of science
Search
Sign In
Create Free Account
albebetin
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Proteins
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.
V. Zamotin
,
Anna L. Gharibyan
,
+5 authors
L. Morozova-Roche
FEBS Letters
2006
Corpus ID: 24239986
Prefibrillar cytotoxicity was suggested as a common amyloid characteristic. We showed two types of albebetin prefibrillar…
Expand
2006
2006
Amyloidogenic properties of the artificial protein albebetin and its biologically active derivatives. The role of electrostatic interactions in fibril formation
M. A. Lavrikova
,
V. Zamotin
,
+5 authors
L. Morozova-Roche
Biochemistry (Moscow)
2006
Corpus ID: 11968623
The artificial protein albebetin (ABB) and its derivatives containing biologically active fragments of natural proteins form…
Expand
2004
2004
An Artificial Protein with the Biological Activity of the Differentiation Factor for the HL-60 Cell Line of Human Promyelocyte Leukemia
R. Chertkova
,
I. Kostanyan
,
M. V. Astapova
,
E. Surina
,
D. Dolgikh
,
M. Kirpichnikov
Russian journal of bioorganic chemistry
2004
Corpus ID: 42359304
The ABB-df artificial protein was prepared by inserting the TGENHR biologically active peptide corresponding to the 41–46…
Expand
2003
2003
[An artificial protein, possessing biological activity of HL-60 human promyelocytic leukemia differentiation factor].
R. Chertkova
,
I. A. Kostanian
,
M. V. Astapova
,
E. Surina
,
D. Dolgikh
,
M. Kirpichnikov
Bioorganicheskaia khimiia
2003
Corpus ID: 8550899
The ABB-df artificial protein was prepared by inserting the TGENHR biologically active peptide corresponding to the 41-46…
Expand
2002
2002
[Introduction of biologically active fragments of interferon-alpha2 and insulin into the artificial protein albebetin affects immunogenicity of the final construct].
O. Bocharova
,
S. A. Moshkovskii
,
+4 authors
M. Kirpichnikov
Voprosy medicinskoj himii
2002
Corpus ID: 26386444
The immunogenicity of the artificial protein albebetin and its derivatives with active peptide fragments was investigated. We…
Expand
1998
1998
[Effect of a biologically active interferon fragment on the structure of the synthetic protein carrier].
I. I. Afasizheva
,
D. Dolgikh
,
+5 authors
M. Kirpichnikov
Biofizika
1998
Corpus ID: 41055674
A biologically active de novo protein albeferon was studied by physical techniques including CD spectroscopy in far and near…
Expand
1996
1996
The de novo protein with grafted biological function: transferring of interferon blast-transforming activity to albebetin.
D. Dolgikh
,
V. Uversky
,
+5 authors
M. Kirpichnikov
Protein Engineering
1996
Corpus ID: 35019809
The de novo protein albebetin has been designed recently to form a predetermined tertiary fold that has not yet been observed in…
Expand
1996
1996
Protein engineering ofDe novo protein with predesigned structure and activity
D. Dolgikh
,
A. Gabrielian
,
V. Uversky
,
M. Kirpichnikov
Applied Biochemistry and Biotechnology
1996
Corpus ID: 25236270
Thede novo protein albebetin has been engineered (J. Mol. Biol. 1992,225, 927–931) to form a predesigned tertiary fold that has…
Expand
1994
1994
A new approach to artificial and modified proteins: theory-based design, synthesis in a cell-free system and fast testing of structural properties by radiolabels.
V. V. Chemeris
,
D. Dolgikh
,
+4 authors
O. Ptitsyn
Protein Engineering
1994
Corpus ID: 35002519
A novel approach to the creation of artificial and modified proteins has been elaborated. The approach includes a sequence design…
Expand
1991
1991
[Preparation and study of albebetin, an artificial protein with a given spatial structure].
D. Dolgikh
,
A. Fedorov
,
+6 authors
O. Ptitsyn
Doklady Akademii nauk SSSR
1991
Corpus ID: 34850060
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required